Filing Flows › Yarrow Bioscience (YARW) › Q1 2025
Yarrow Bioscience (YARW) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Yarrow Bioscience (YARW) reported revenue of $202K for the first quarter 2025 (Q1 2025), +106% from a year earlier and +140% from the quarter before.
Yarrow Bioscience, Q1 2025: revenue $202K (+106% year over year), net loss $8.6M, operating cash flow −$11.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $202K | +140% | +106% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$8.6M | — | — |
| Operating cash flow | −$11.5M | — | — |
What changed
Revenue was $202K in Q1 2025, up 106% year over year and up 140% from the previous quarter.
Operating costs exceeded revenue by $9.2M, an operating margin of -4553.0%. Total costs grew 26% against revenue growth of 106%. The fastest-growing cost line was Research & development (+65%). The quarter ended with a net loss of $8.6M, narrower than the previous quarter's $12.0M loss.
Operating cash flow was −$11.5M. Non-cash charges added back $6K of depreciation and $763K of share-based compensation. Working capital and other items used $3.6M.
Questions
What was Yarrow Bioscience's revenue in the first quarter 2025?
Yarrow Bioscience (YARW) reported revenue of $202K for the first quarter 2025 (Q1 2025), +106% from a year earlier and +140% from the quarter before.
Source: Yarrow Bioscience 10-Q on SEC EDGAR.